High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma

Clinical and Experimental Medicine

Volumn 12, Issue 3, 2012, Pages 165-171

  Falzetti, Franca ^a   Ianni, Mauro Di ^a   Ballanti, Stelvio ^a   Iodice, Giuseppe ^b   Reale, Antonia ^b   Minelli, Olivia ^c   Serio, Gabriella ^d   Martelli, Massimo F ^a   Dammacco, Franco ^b   Vacca, Angelo ^b   Ria, Roberto ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Perugia General Hospital   (Italy)

^d UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Autologous stem cell transplantation; Conditioning regimen; High dose chemotherapy; Non Hodgkin lymphoma; Survival

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THIOTEPA; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CD34 SELECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG FEVER; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LENGTH OF STAY; LEUKAPHERESIS; LEUKOPENIA; LIVER FAILURE; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SKIN MANIFESTATION; STAPHYLOCOCCUS INFECTION; STEM CELL MOBILIZATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865522655     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0157-2     Document Type: Article

References (40)

1. K Garber 2001 Lymphoma rate rise continues to baffle researchers J Natl Cancer Inst 93 494 496 11287438 10.1093/jnci/93.7.494 1:STN:280: DC%2BD3M3gtVCqsA%3D%3D
2. G Salles B Coiffier 1999 Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma Baillieres Best Pract Res Clin Haematol 12 151 169 11000990 10.1053/beha.1999.0014 1:STN:280: DC%2BD3cvksl2ktw%3D%3D
3. AZ Rohatiner PW Johnson CG Price SJ Arnott JA Amess AJ Norton E Dorey K Adams JS Whelan J Matthews 1994 Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma J Clin Oncol 12 1177 1184 8201380 1:STN:280:DyaK2c3mtValtg%3D%3D
4. T Philip C Guglielmi A Hagenbeek R Somers H Van der Lelie D Bron P Sonneveld C Gisselbrecht JY Cahn JL Harousseau B Coiffier P Biron, et al. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma N Engl J Med 333 1540 1545 7477169 10.1056/NEJM199512073332305 1:STN:280:DyaK28%2FmslCgtQ%3D%3D
5. RI Fisher ER Gaynor S Dahlberg MM Oken TM Grogan EM Mize JH Glick CA Coltman Jr TP Miller 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1002 1006 7680764 10.1056/NEJM199304083281404 1:STN:280: DyaK3s7ps1Kmtg%3D%3D
6. I Aksentijevich RJ Jones RF Ambinder E Garrett-Mayer IW Flinn 2006 Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma Biol Blood Marrow Transplant 12 965 972 16920563 10.1016/j.bbmt.2006.05.018
7. A Josting M Reiser U Rueffer B Salzberger V Diehl A Engert 2000 Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 18 332 339 10637247 1:STN:280: DC%2BD3c7gsFekug%3D%3D
8. JM Vose 1998 High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma Ann Oncol 9 Suppl 1 S1 S3 9581234 10.1093/annonc/9.suppl-1.S1
9. MA Shipp MD Abeloff KH Antman G Carroll A Hagenbeek M Loeffler E Montserrat JA Radford G Salles N Schmitz M Symann JO Armitage, et al. 1999 International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury J Clin Oncol 17 423 429 10458261 1:STN:280:DyaK1MzosFCnsQ%3D%3D
10. MS Lee KS Chang F Cabanillas EJ Freireich JM Trujillo SA Stass 1987 Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification Science 237 175 178 3110950 10.1126/science.3110950 1:CAS:528:DyaL2sXlsVymtbg%3D
11. JG Sharp SS Joshi JO Armitage P Bierman PF Coccia DS Harrington A Kessinger DA Crouse SL Mann DD Weisenburger 1992 Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique Blood 79 1074 1080 1737092 1:STN:280:DyaK387ksV2kuw%3D%3D
12. R Chopra AK McMillan DC Linch S Yuklea G Taghipour R Pearce KG Patterson AH Goldstone 1993 The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood 81 1137 1145 8443375 1:STN:280:DyaK3s7osVejsQ%3D%3D
13. PJ Stiff S Dahlberg SJ Forman AR McCall SJ Horning AP Nademanee KG Blume M LeBlanc RI Fisher 1998 Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens-a Southwest Oncology Group trial J Clin Oncol 16 48 55 9440722 1:STN:280:DyaK1c7gtFKksA%3D%3D
14. KP Papadopoulos W Noguera-Irizarry L Wiebe CS Hesdorffer J Garvin GL Nichols LH Vahdat KM Lo D Skerrett D Bernstein E Sharpe DG Savage 2005 Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma Bone Marrow Transpl 36 491 497 10.1038/sj.bmt.1705103 1:CAS:528:DC%2BD2MXpslaksr4%3D
15. T Ahmed K Rashid F Waheed R Kancherla Z Qureshi A Hoang J Richter MF Ali R Goldberg D Liu K Seiter 2005 Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant Leuk Lymphoma 46 405 414 15621831 10.1080/10428190400019826 1:CAS:528:DC%2BD2cXhtFCqurvK
16. JP Glossmann JO Staak L Nogova V Diehl C Scheid J Kisro HE Reis N Peter A Engert A Josting 2005 Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma Ann Hematol 84 517 525 15759115 10.1007/s00277-005-1011-y 1:CAS:528:DC%2BD2MXlvVynsb8%3D
17. A Fontelonga AJ Kelly FR MacKintosh S Hall P Monroe GS Wilson D Shaft A Ruthven JL Ascensao 1997 A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma Bone Marrow Transpl 19 983 988 10.1038/sj.bmt.1700783 1:STN:280:DyaK2szhtlSgug%3D%3D
18. UB Chaudhary LE Damon HS Rugo CA Linker W Navarro EJ Small 2005 High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer Am J Clin Oncol 28 130 137 15803005 10.1097/01.coc.0000144264.00518.47 1:CAS:528:DC%2BD2MXktVSms7w%3D
19. SI Bearman FR Appelbaum A Back FB Petersen CD Buckner KM Sullivan HG Schoch LD Fisher ED Thomas 1988 Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 6 1562 1568 3049951 1:STN:280:DyaL1M%2FhtVyksQ%3D%3D
20. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 135 185
21. DL Longo PL Duffey RC Young SM Hubbard DC Ihde E Glatstein JC Phares ES Jaffe WJ Urba VT DeVita Jr 1992 Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure J Clin Oncol 10 210 218 1732422 1:STN:280:DyaK387itF2gsg%3D%3D
22. R Saez S Dahlberg FR Appelbaum RJ Hartsock F Lemaistre CA Coltman Jr RI Fisher 1994 Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study Hematol Oncol 12 75 85 8070756 10.1002/hon.2900120205 1:STN:280:DyaK2czltVejuw%3D%3D
23. F Cabanillas WS Velasquez P McLaughlin S Jagannath FB Hagemeister JR Redman F Swan MA Rodriguez 1988 Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease Semin Hematol 25 Suppl 2 47 50 3041599 1:STN:280:DyaL1c3ptVOitQ%3D%3D
24. AM Gianni M Bregni S Siena C Brambilla M Di Nicola F Lombardi L Gandola C Tarella A Pileri F Ravagnani P Valagussa G Bonadonna 1997 High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma N Engl J Med 336 1290 1297 9113932 10.1056/NEJM199705013361804 1:CAS:528:DyaK2sXjt1aqu7Y%3D
25. C Haioun E Lepage C Gisselbrecht G Salles B Coiffier P Brice A Bosly P Morel C Nouvel H Tilly P Lederlin C Sebban, et al. 2000 Survival benefit of high dose therapy in poor risk non Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol, a groupe d'Etude des lymhomes de l'Adulte study J Clin Oncol 18 3025 3030 10944137 1:STN:280:DC%2BD3cvivFCkug%3D%3D
26. U Kaiser I Uebelacker U Abel J Birkmann L Trümper H Schmalenberg T Karakas B Metzner DK Hossfeld HG Bischoff A Franke M Reiser, et al. 2002 Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "Aggressive" lymphoma J Clin Oncol 20 4413 4419 12431962 10.1200/JCO.2002.07.075 1:CAS:528:DC%2BD38XosFCjs7k%3D
27. M Martelli F Gherlinzoni A De Renzo PL Zinzani A De Vivo M Cantonetti B Falini S Storti G Meloni M Rizzo AL Molinari F Lauria, et al. 2003 Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomised trial J Clin Oncol 21 1255 1262 12663712 10.1200/JCO.2003.01.117
28. N Milpied E Deconinck F Gaillard V Delwail C Foussard C Berthou R Gressin V Lucas P Colombat JL Harousseau 2004 Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang N Engl J Med 350 1287 1295 15044639 10.1056/NEJMoa031770 1:CAS:528:DC%2BD2cXisFyiur4%3D
29. C Gisselbrecht E Lepage T Molina B Quesnel G Fillet P Lederlin B Coiffier H Tilly J Gabarre F Guilmin O Hermine F Reyes 2002 Shortened first-line high dose chemotherapy for patients with poor-prognosis aggressive lymphoma. Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 20 2472 2479 12011124 10.1200/JCO.2002.02.125 1:CAS:528:DC%2BD38XksFakurs%3D
30. MA Shipp D Neuberg M Janicek GP Canellos LN Shulman 1995 High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study J Clin Oncol 13 2916 2923 8523055 1:CAS:528:DyaK28XmslOmsg%3D%3D
31. H Tilly N Mounier P Lederlin J Brière B Dupriez C Sebban A Bosly P Biron C Nouvel R Herbrecht D Bordessoule B Coiffier 2000 Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study J Clin Oncol 18 1309 1315 10715302 1:CAS:528:DC%2BD3cXit12ltLs%3D
32. SM Talbot DA Westerman AP Grigg GC Toner M Wolf J Bishop J McKendrick J Zalcberg J Levi RM Fox MD Green 1999 Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicine in patients with non-Hodgkin's lymphoma and advanced solid tumors Ann Oncol 10 907 914 10509151 10.1023/A:1008353522601 1:STN:280: DyaK1MvjvVGltQ%3D%3D
33. DW Blayney ML LeBlanc T Grogan ER Gaynor RA Chapman CH Spiridonidis SA Taylor SI Bearman TP Miller RI Fisher 2003 Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349) J Clin Oncol 21 2466 2473 12829664 10.1200/JCO.2003.06.137 1:CAS:528:DC%2BD2cXptlCktrg%3D
34. M Balzarotti M Spina B Sarina M Magagnoli L Castagna I Milan C Ripa F Latteri D Bernardi A Bertuzzi A Nozza M Roncalli, et al. 2002 Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide Ann Oncol 13 1341 1346 12196358 10.1093/annonc/mdf242 1:STN:280:DC%2BD38vjvVGjsw%3D%3D
35. RM Meyer IC Quirt JR Skillings MC Cripps VH Bramwell BH Weinerman MK Gospodarowicz BF Burns AM Sargeant LE Shepherd B Zee WM Hryniuk 1993 Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma N Engl J Med 329 1770 1776 7694148 10.1056/NEJM199312093292404 1:STN:280:DyaK2c%2FltVSlsg%3D%3D
36. H Tilly E Lepage B Coiffier M Blanc R Herbrecht A Bosly M Attal G Fillet C Guettier TJ Molina C Gisselbrecht F Reyes 2003 Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte Blood 102 4284 4289 12920037 10.1182/blood-2003-02-0542 1:CAS:528: DC%2BD3sXpslGrsrg%3D
37. M Pfreundschuh L Trumper M Kloess R Schmits AC Feller C Rübe M Reiser DK Hossfeld B Metzner D Hasenclever N Schmitz B Glass, et al. 2004 Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 104 626 633 14982884 10.1182/blood-2003-06-2094 1:CAS:528:DC%2BD2cXmtlCkt7k%3D
38. M Pfreundschuh L Trümper M Kloess R Schmits AC Feller C Rübe C Rudolph M Reiser DK Hossfeld H Eimermacher D Hasenclever N Schmitz, et al. 2004 Two-weekly or 3-weekly CHOP Chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. German High-Grade Non-Hodgkin's Lymphoma Study Group Blood 104 634 641 15016643 10.1182/blood-2003-06-2095 1:CAS:528:DC%2BD2cXmtlCkt7Y%3D
39. DW Milligan MC Ruiz De Elvira HJ Kolb AH Goldstone G Meloni AZ Rohatiner P Colombat N Schmitz 1999 Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation Br J Haematol 106 1020 1026 10520006 10.1046/j.1365-2141.1999.01627.x 1:STN:280:DyaK1MvltFaquw%3D%3D
40. U Vitolo AM Liberati MG Cabras M Federico E Angelucci L Baldini C Boccomini M Brugiatelli R Calvi G Ciccone A Genua GL Deliliers A Levis G Parvis E Pavone F Salvi M Sborgia E Gallo Intergruppo Italiano Linfomi, et al. 2005 High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial Haematologica 90 793 801 15951292 1:CAS:528: DC%2BD2MXnvVWku7s%3D